Clinical trials: Antineoplastics Toxicity
Urologic Neoplasms, Urogenital Neoplasms
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment…
- Conditions
- Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- TURANDORELA (NCT06237920)
- Testing
- Nivolumab, Relatlimab
- Where
- 9 sites in Netherlands
- Volunteers
- 90 people
- Sponsor
- The Netherlands Cancer Institute
Heart Failure, Cardiotoxicity
The STOP-MED CTRCD Trial
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients.
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity
- Trial name
- STOP-MED CTRCD (NCT06183437)
- Testing
- Stopping Heart Failure Medication(s)
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 335 people
- Sponsor
- Dinesh Thavendiranathan
Kidney Injury, Antineoplastics Toxicity
Immune Checkpoint Inhibitors Nephrotoxicity
In recent years, immunotherapy has been postulated as one of the most effective strategy in the fight against cancer. The greatest success in this field has been achieved through the inhibition of molecules involved in the brake…
- Trial name
- NCT04902846
- Testing
- Early kidney damage biomarkers, Predisposition to kidney injury biomarkers
- Where
- 2 sites in Spain
- Volunteers
- 220 people
- Sponsor
- R. Laura Vicente Vicente